Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 11/20 | 0.78 |
| ▸ | YAP1 | P46937 | 1/20 | 0.70 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.70 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.67 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.67 |
| ▸ | MPO | P05164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26735295 | 0.90 | RXFP1 (0.64) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| SCHEMBL15528884 | 0.87 | RXFP1 (1.00) | RXFP1 | |
| Flufenamic Acid SCHEMBL29356958 | 0.87 | RXFP1 (0.75) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| Flufenamic Acid SCHEMBL17497 | 0.87 | RXFP1 (0.75) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| SCHEMBL9271694 | 0.86 | RXFP1 (0.70) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| SCHEMBL9522037 | 0.86 | YAP1 (0.74) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| SCHEMBL9270625 | 0.86 | RXFP1 (0.73) | RXFP1YAP1TEAD4TEAD2MPO | |
| Flufenamic Acid SCHEMBL11524554 | 0.86 | RXFP1 (0.73) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| Flufenamic Acid SCHEMBL9845499 | 0.86 | RXFP1 (0.73) | RXFP1YAP1TEAD4TEAD2AKR1C3 | |
| SCHEMBL14853341 | 0.85 | YAP1 (0.77) | RXFP1YAP1TEAD4TEAD2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4272761-A2 | COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS | Medicon Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2018064354-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | MEDICON PHARMACEUTICALS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20150306232-A1 | HYDROGELATORS COMPRISING D-AMINO ACIDS | BRANDEIS UNIVERSITY | 2015-10-29 | — | — | US | disclosed |
| US-8278342-B2 | Therapeutic compounds for blocking DNA synthesis of pox viruses | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-11 | — | — | US | disclosed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-7579334-B2 | Compounds with anti-inflammatory activity | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2009-08-25 | — | — | US | disclosed |
| US-7579334-B2 | Compounds with anti-inflammatory activity | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB (HR) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035887-A1 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES | TPX2, POLB, POLM | RXFP1 2073/4885YAP1 1054/4885TEAD4 409/4885 |
| US-20230293557-A1 | COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS | PDE6C, PDE6H, PDE6D | RXFP1 1635/4885YAP1 3830/4885TEAD4 3635/4885 |
| US-20150306232-A1 | HYDROGELATORS COMPRISING D-AMINO ACIDS | DNPEP, S100A10, S100A11 | RXFP1 411/4885YAP1 514/4885TEAD4 1696/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | RXFP1 1037/4885YAP1 707/4885TEAD4 1079/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | RXFP1 1037/4885YAP1 707/4885TEAD4 1079/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | RXFP1 1037/4885YAP1 707/4885TEAD4 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.